HB 498 creates an advisory task force to review and recommend annual adjustments to state reimbursement rates paid to healthcare agencies in Tennessee. The task force, composed of 6 appointed members (3 by each legislative chamber, representing different health professions) and ex-officio agency representatives, will focus on ensuring rates cover agency costs, staff salaries, and administrative needs. It must submit annual recommendations by August 1, starting in 2026, to state officials and legislative committees, considering factors like provider costs, staff compensation, and workforce shortages. The bill directly affects healthcare agencies providing state-funded services, aiming to make reimbursement rates more adequate without changing existing funding levels.
HB 502 expands TennCare coverage to include diagnosis (including genetic testing) and treatment for Kleefstra syndrome, a rare genetic disorder affecting development and multiple body systems. It requires TennCare to provide this coverage in the same manner and extent as for autism spectrum disorder, Down syndrome (Trisomy 21), and other similar genetic disorders, when medically necessary. This applies to all enrolled individuals with Kleefstra syndrome and covers therapies, medications, assistive devices, and interventions aimed at improving quality of life. The law takes effect July 1, 2025, after being signed by the Governor in April 2025.
HB 1201 creates a temporary "foreign training license" for internationally licensed physicians in Tennessee who meet specific criteria. It directly affects physicians trained outside the U.S. but holding valid licenses in their home countries, requiring them to provide proof of an AMA-approved medical education, an ECFMG certificate, three years of postgraduate training (or seven years of practice), and current good standing in their home licensing country. The license is tied to a specific Tennessee healthcare employer, requiring applicants to have a job offer from that provider and restricting practice to that employer unless the board is notified of a change. After two years of active practice in Tennessee under this license, physicians may qualify for a full, unrestricted medical license. The bill takes effect July 1, 2025.
HJR 80 designates May 2025 as "National Hypertension Month" in Tennessee. The resolution urges healthcare providers, insurers, and TennCare to promote hypertension awareness and support coverage for renal denervation therapies, which treat resistant hypertension. It advocates for policy changes to improve access to innovative treatments but does not create new legal requirements. As a symbolic resolution, it encourages state-level action without mandating specific outcomes.
HJR 69 is a non-binding resolution urging Tennessee to adopt a comprehensive plan to address chronic disease. It proposes four key areas: reforming food access (e.g., restricting junk food in SNAP benefits, increasing healthy food availability), integrating health education in schools, improving government health standards (like banning toxins and updating FDA processes), and requiring nutritious meals in state facilities. The resolution directs state officials to support these principles and participate in an annual "Make Tennessee Healthy" summit. It does not create new laws but calls for policy shifts to reduce preventable health issues affecting Tennesseans.
HB 383 requires Tennessee's health commissioner to add alpha-gal syndrome - a rare meat allergy triggered by tick bites - to the state's official list of reportable diseases by July 1, 2025. Healthcare providers must then report diagnosed cases to the Department of Health under existing rules. This bill directly affects medical professionals who will need to submit these reports and public health officials who will track the condition. The law amends Tennessee Code Titles 4, 63, and 68 to implement this change, effective March 26, 2025.
SB 282, the "Individualized Investigational Treatment Act," creates a legal framework for patients with life-threatening or severely debilitating illnesses to access personalized medical treatments (like gene therapies or vaccines tailored to their genetic profile) when standard FDA-approved options have been exhausted. It directly affects eligible patients (who must meet specific criteria including physician attestation and written informed consent) and eligible facilities (those complying with federal human subjects protections). Key provisions require detailed written consent covering all treatment options, risks, and financial liability, while clarifying that insurers, health plans, and providers are **not obligated** to cover these treatments or related costs (TCA §§ 63-6-1304(a)-(d)). The law takes effect July 1, 2025, and explicitly states that heirs cannot be held liable for unpaid treatment debts if a patient dies during treatment (TCA § 63-6-1305).
This bill adds hepatitis C antibody (anti-HCV) testing to the standard blood screening required for all pregnant women in Tennessee during initial prenatal visits and between weeks 28-32 of pregnancy. If the anti-HCV test is reactive, labs must automatically conduct a follow-up HCV RNA test without requiring additional orders. It directly affects all pregnant women receiving routine prenatal care in Tennessee, expanding the required screening panel to include hepatitis C alongside existing tests for syphilis, rubella, and hepatitis B. The changes take effect July 1, 2025, and align hepatitis C testing protocols with existing disease reporting requirements for maternal health.
HB 15 would allow Tennessee's governor to expand Medicaid eligibility exclusively for sickle cell disease treatment, in alignment with federal law. The bill requires the governor to negotiate with federal health officials (Centers for Medicare and Medicaid Services) on the specific terms of this expansion. This change would directly affect Tennessee residents diagnosed with sickle cell disease by potentially providing Medicaid coverage for their treatment. The expansion is strictly limited to sickle cell disease and must comply with the federal Patient Protection and Affordable Care Act.
HB 14 clarifies that Tennessee's definition of "abortion" does not include contraceptive use (such as birth control devices, medications, or procedures intended to prevent pregnancy) or the disposal of unimplanted embryos from fertility treatments (including related healthcare services and medications). The bill directly affects healthcare providers, patients, and fertility clinics by explicitly excluding these common medical practices from criminal abortion statutes. It amends Tennessee Code Sections 39-15-213 and related provisions to define these exclusions. The bill failed in the Health Committee's Population Health Subcommittee on March 18, 2025, and did not advance to the full legislature.
